GrantRover ↗

← Tüm fırsatlar

National Institutes of Health · ABD

Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)

Full title in the source: Catalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)

Açık

Başvurular 23 Aralık 2027 tarihinde kapanıyor. Uygun başvuru sahibi türleri (kaynakta): City or township governments, For profit organizations other than small businesses, Others (see text field entitled "Additional Information on Eligibility" for clarification) ve 12 diğer.

Son başvuru
23 Aralık 2027 (403 gün kaldı)
Hibe tutarı
Belirtilmemiş — resmi çağrıya bakın
Destek oranı
Zorunlu eş finansman belirtilmemiş; destek oranı belirtilmemiş
Eş finansman
Gerekli değil
Olası başvuru sahipleri
Kamu kurumları, KOBİ’ler / girişimler, Şirketler, Kâr amacı gütmeyenler, Üniversiteler ve araştırma Kaynak kategorilerinden veya program kurallarından; uygunluğa çağrı karar verir.
Fon sağlayıcı
National Institutes of Health
Referans
RFA-HL-26-020
Destek listesi (ABD)
93.233 National Center on Sleep Disorders Research; 93.837 Cardiovascular Diseases Research; 93.838 Lung Diseases Research; 93.839 Blood Diseases and Resources Research
Son kontrol
13 Kasım 2026

Resmi çağrıyı aç ↗ Son tarihi takvime ekle

Resmi açıklamalar fon sağlayıcının dilindedir (çoğunlukla İngilizce); bu sayfadaki özet ve temel bilgiler Türkçedir.

Çağrı hakkında

The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and entrepreneurship. This specific Catalyze Product Definition initiative will provide the early stage translational support needed for prototype testing/design modification, assay development for diagnostic disease targets, and development of research tools for use in the treatment of HLBS diseases and disorders. Following successful completion of the program, it is expected that the potential products will be poised to move forward for in vivo testing (optimization, safety, efficacy) with additional support from NIH and/or other federal and private programs. This initiative has a companion initiative that supports development of therapeutics and combination products and is also part of a suite of innovation grants to advance projects to the point where they can meet the entry criteria for the NHLBI Catalyze Preclinical Program.

Kimler başvurabilir

Other Eligible Applicants include the following:

Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

Başvuru sahibi kategorileri yalnızca bir başlangıç noktasıdır. Uygunluğa resmi çağrı karar verir.

Konular

Health

Nasıl başvurulur

  1. Read the full notice of funding opportunity (NOFO) linked from the official page: eligibility, cost sharing and evaluation criteria.
  2. Make sure your organisation has an active SAM.gov registration and Unique Entity ID (UEI); registration can take several weeks.
  3. For NIH: the organisation and the principal investigator also need eRA Commons accounts; applications are usually submitted through Grants.gov (for example with ASSIST).
  4. Prepare the required forms, narrative, budget and attachments exactly as the NOFO specifies.
  5. Submit before the deadline and keep the tracking number. Check for amendments before you submit.

From the call text

Who can apply
Not stated in the call text we hold — check the official page
Company stage
Not stated in the call text we hold — check the official page
Single applicant or consortium
Not stated in the call text we hold — check the official page
Where applicants must be based
Not stated in the call text we hold — check the official page
Where to apply
Not stated in the call text we hold — check the official page

İletişim

National Institutes of Health · grantsinfo@nih.gov · 301-402-2541

Resmi kaynaklar

Resmi çağrı sayfası · Fon sağlayıcının program sayfası

Bu sayfadaki bilgiler resmi kaynaktan alınmıştır ve en son 13 Kasım 2026 tarihinde kontrol edilmiştir. Sonraki değişiklikler dahil, fon sağlayıcının kendi belgeleri her zaman önceliklidir.

National Institutes of Health: diğer çağrılar

National Institutes of Health ABD

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High… (R34 Clinical Trial Required)

PAR-25-274

The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychologic…

National Institutes of Health ABD

Investigator Initiated Clinical Trials of Complementary and Integrative… (R01 Clinical Trial Required)

PAR-25-268

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and conducted clinical trials to assess the efficacy…

National Institutes of Health ABD

NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

PAR-25-267

This notice of funding opportunity (NOFO) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical…

National Institutes of Health ABD

Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)

PAR-25-158

This Notice of Funding Opportunity (NOFO) focuses on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) throughout the lifespan. The inten…